Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges

被引：146

作者：

Dufour, Jean-Francois ^{[1
,2
]}

Caussy, Cyrielle ^{[3
,4
]}

Loomba, Rohit ^{[5
]}

机构：

[1] Univ Bern, Dept Clin Res, Hepatol, CH-3010 Bern, Switzerland

[2] Inselspital Bern, Univ Clin Visceral Surg & Med, Bern, Switzerland

[3] Univ Lyon 1, Hosp Civils Lyon, Ctr Hosp Lyon Sud Endocrinol Diabete & Nutr, Lyon, France

[4] Univ Calif San Diego, NAFLD Res Ctr, La Jolla, CA 92093 USA

[5] Univ Calif San Diego, NAFLD Res Ctr, Dept Med, Div Gastroenterol & Hepatol, La Jolla, CA 92093 USA

来源：

GUT | 2020年 / 69卷 / 10期

基金：

瑞士国家科学基金会;

关键词：

nonalcoholic steatohepatitis; hepatobiliary disease; liver; FATTY LIVER-DISEASE; TYPE-2; DIABETES-MELLITUS; CHRONIC KIDNEY-DISEASE; CARDIOVASCULAR OUTCOMES; INSULIN-RESISTANCE; ADVANCED FIBROSIS; HIGH PREVALENCE; OBESE-PATIENTS; PLACEBO; ASSOCIATION;

D O I：

10.1136/gutjnl-2019-319104

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Non-alcoholic steatohepatitis (NASH) is becoming a leading cause of cirrhosis with the burden of NASH-related complications projected to increase massively over the coming years. Several molecules with different mechanisms of action are currently in development to treat NASH, although reported efficacy to date has been limited. Given the complexity of the pathophysiology of NASH, it will take the engagement of several targets and pathways to improve the results of pharmacological intervention, which provides a rationale for combination therapies in the treatment of NASH. As the field is moving towards combination therapy, this article reviews the rationale for such combination therapies to treat NASH based on the current therapeutic landscape as well as the advantages and limitations of this approach.

引用

页码：1877 / 1884

页数：8

共 50 条

[41] Statins and non-alcoholic steatohepatitis
Athyros, Vasilios G.
Katsiki, Niki
Karagiannis, Asterios
Mikhailidis, Dimitri P.
JOURNAL OF HEPATOLOGY, 2016, 64 (01) : 241 - 242
[42] Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Current concepts and remaining challenges
Hashimoto, Etsuko
Tokushige, Katsutoshi
Ludwig, Jurgen
HEPATOLOGY RESEARCH, 2015, 45 (01) : 20 - 28
[43] Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis
Bonkovsky, HL
Jawaid, Q
Tortorelli, K
LeClair, P
Cobb, J
Lambrecht, RW
Banner, BF
JOURNAL OF HEPATOLOGY, 1999, 31 (03) : 421 - 429
[44] Role of iron in non-alcoholic and alcoholic steatohepatitis
Deugnier, Y
Moirand, R
Mendler, MH
Brissot, P
STEATOHEPATITIS (NASH AND ASH), 2001, 121 : 100 - 103
[45] The genetic basis for non-alcoholic and alcoholic steatohepatitis
Day, CP
Daly, AK
STEATOHEPATITIS (NASH AND ASH), 2001, 121 : 43 - 53
[46] Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
Eslami, Layli
Merat, Shahin
Malekzadeh, Reza
Nasseri-Moghaddam, Siavosh
Aramin, Hermineh
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (12):
[47] Drug Therapy for non-alcoholic Steatohepatitis MAESTRO-NASH
Bantel, Heike
Nitschmann, Sirka
INNERE MEDIZIN, 2024, 65 (06): : 627 - 628
[48] A new approach to drug therapy in non-alcoholic steatohepatitis (NASH)
Fehér, J
Lengyel, G
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2003, 31 (06) : 537 - 551
[49] Pharmacological therapy for non-alcoholic steatohepatitis: How efficient are thiazolidinediones?
Ratziu, Vlad
Pienar, Loredana
HEPATOLOGY RESEARCH, 2011, 41 (07) : 687 - 695
[50] EFFICACY OF COMBINATION THERAPY WITH ELOBIXIBAT AND COLESTYRAMINE FOR NON-ALCOHOLIC STEATOHEPATITIS MODEL MICE TO PREVENT ARTERIOSCLEROSIS.
Iwaki, Michihiro
Kessoku, Takaomi
Ozaki, Anna
Kasai, Yuki
Kobayashi, Takashi
Ogawa, Yuji
Honda, Yasushi
Nogami, Asako
Imajo, Kento
Yoneda, Masato
Saito, Satoru
Nakajima, Atsushi
HEPATOLOGY, 2020, 72 : 324A - 325A

← 1 2 3 4 5 →